TickerFacts.

Neuphoria Therapeutics Inc. (NEUP): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$15.79M
Year ended 2026-06-30
2023-06-30: -$21.32M2024-06-30: -$17.23M2025-06-30: -$466.2K2026-06-30: -$15.79M-$15.79M
2023-06-30 EBITDA (USD) 2026-06-30
Period endedEBITDAChange YoYSource filing
2026-06-30-$15.79Mn/m2026-09-18, From 2025-07-01
2025-06-30-$466.2Kn/m2026-09-18, From 2024-07-01
2024-06-30-$17.23Mn/m2025-09-29, From 2023-07-01
2023-06-30-$21.32Mn/a2024-09-30, From 2022-07-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Neuphoria Therapeutics Inc. (NEUP)2026-06-30-$15.79Mn/m
Longeveron Inc. (LGVN)2025-12-31-$22.49Mn/m
China SXT Pharmaceuticals, Inc. (SXTC)2026-03-31-$7.05Mn/m
Vistagen Therapeutics, Inc. (VTGN)2026-03-31-$71.93Mn/m
IGC Pharma, Inc. (IGC)2025-03-31-$6.83Mn/m
Dare Bioscience, Inc. (DARE)2025-12-31-$11.92Mn/m
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31-$7.72Mn/m
Northwest Biotherapeutics Inc (NWBO)2025-12-31-$57.85Mn/m
Shattuck Labs, Inc. (STTK)2025-12-31-$47.81Mn/m

Compare NEUP, LGVN, SXTC, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗